A Shot For Bipolar I Disorder? Identifying Appropriate Patient Profiles For Maintenance Therapy With Long Acting Injectable Medications

Description

Click here to register for the 6:00 pm ET rebroadcast. Please note: Due to high levels of interest, please access this webinar via your computer.

For more information on this topic watch: Discussion Of Identifying Profiles Of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With A Long-Acting Injectable Antipsychotic

Bipolar I Disorder is a chronic mental health condition. Recurrence of mood episodes and functional deterioration are related. A question that deserves further discussion is, “At what point is maintenance therapy warranted?” In this roundtable discussion, Otsuka Senior MSL, Dr. Fatima Sadat, sits down with Drs. Mauricio Tohen and Joseph Goldberg to uncover issues related to identifying profiles of Bipolar I Disorder patients who may be considered for long acting injectable medication maintenance therapy.

Featuring:

• Mauricio Tohen, MD, DrPH, MBA
  Professor and Chair, Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, New Mexico
• Joseph F. Goldberg, MD
  Clinical Professor, Department of Psychiatry, Icahn School of Medicine, Mount Sinai, New York City, New York
• Fatima Sadat, PharmD
  Senior Medical Science Liaison, Otsuka Pharmaceutical Development and Commercialization Inc.

Dr. Mauricio Tohen is a University Distinguished Professor and Chairman of the Department of Psychiatry & Behavioral Sciences at the University of New Mexico HSC in Albuquerque NM, USA. In 2014 Dr Tohen was recognized in Thomson Reuter’s “The World’s Most Influential Scientific Minds.  He is 1 of 100 scientists worldwide recognized in the Psychiatry/psychology category. Dr Tohen has published over 350 publications and has over 20,000 scientific citations. In 2016, the International Society for Bipolar disorders awarded him the Mogens Schou award for Education and Teaching.

Dr. Joseph F. Goldberg is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai.  Dr .Goldberg serves on the Board of Directors for the American Society of Clinical Psychopharmacology and has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology.

Dr. Mauricio Tohen and Dr. Joseph F. Goldberg are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.

Fatima Sadat, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Event Speakers

Mauricio Tohen, MD, DrPH, MBA
Professor and Chair, Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, New Mexico

Dr. Mauricio Tohen is a University Distinguished Professor and Chairman of the Department of Psychiatry & Behavioral Sciences at the University of New Mexico HSC in Albuquerque NM, USA. In 2014 Dr Tohen was recognized in Thomson Reuter’s “The World’s Most Influential Scientific Minds.  He is 1 of 100 scientists worldwide recognized in the Psychiatry/psychology category. Dr Tohen has published over 350 publications and has over 20,000 scientific citations. In 2016, the International Society for Bipolar disorders awarded him the Mogens Schou award for Education and Teaching.

Joseph F. Goldberg, MD
Clinical Professor, Department of Psychiatry, Icahn School of Medicine, Mount Sinai, New York City, New York

Dr. Joseph F. Goldberg is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai.  Dr .Goldberg serves on the Board of Directors for the American Society of Clinical Psychopharmacology and has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology.

Fatima Sadat, PharmD
Senior Medical Science Liaison, Otsuka Pharmaceutical Development and Commercialization Inc.